Welcome to Scribd. Sign in or start your free trial to enjoy unlimited e-books, audiobooks & documents.Find out more
Download
Standard view
Full view
of .
Look up keyword
Like this
0Activity
0 of .
Results for:
No results containing your search query
P. 1
Social Anxiety Disorders (SAD) Therapeutics - Pipeline Assessment and Market Forecasts to 2019

Social Anxiety Disorders (SAD) Therapeutics - Pipeline Assessment and Market Forecasts to 2019

Ratings:
(0)
|Views: 0|Likes:
Published by aarkstor

More info:

Published by: aarkstor on Jun 28, 2012
Copyright:Attribution Non-commercial

Availability:

Read on Scribd mobile: iPhone, iPad and Android.
download as DOCX, PDF, TXT or read online from Scribd
See more
See less

12/23/2012

pdf

text

original

 
 
Social Anxiety Disorders (SAD) Therapeutics - PipelineAssessment and Market Forecasts to 2019
Summary
Company, the industry analysis specialist, has released its new report, “Social Anxiety Disorders (SAD)
Therapeutics - Pipeline Assessment and
Market Forecasts to 2019”. The report is an essential source of 
 
information and analysis on the global Social Anxiety Disorders (SAD) Therapeutics market. The reportidentifies the key trends shaping and driving the global Social Anxiety Disorders (SAD) Therapeutics market.
 
The report also provides insights on the prevalent competitive landscape and the emerging players expected tosignificantly alter the market positioning of the current market leaders. Most importantly, the report provides
 
valuable insights on the pipeline products within the global Social Anxiety Disorders (SAD) Therapeutics sector.
 
This report is built using data and information sourced from proprietary databases, primary and secondaryresearch and in-house analysis by Company team of industry experts.
 
Scope
 
The report provides information on the key drivers and challenges of the Social Anxiety Disorders (SAD)Therapeutics market. Its scope includes -
 
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Social Anxiety Disorders(SAD) Therapeutics market revenues data from 2006 to 2011, forecast for eight years to 2019.
 
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developedand emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
 
- Analysis of the current and future competition in the seven key countries Social Anxiety Disorders (SAD)Therapeutics market.
 
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently
 
researched to provide a qualitative analysis of its implications.- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the
 
implications for the Social Anxiety Disorders (SAD) Therapeutics market.- Analysis of key recent licensing and partnership agreements in Social Anxiety Disorders (SAD) Therapeutics
 
marketReasons to buyThe report will enhance your decision making capability. It will allow you to -- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and
 
technologies and by identifying the companies with the most robust pipeline.
 
- Develop business strategies by understanding the trends shaping and driving the global Social AnxietyDisorders (SAD) Therapeutics market.
 
- Drive revenues by understanding the key trends, innovative products and technologies, market segments andcompanies likely to impact the global Social Anxiety Disorders (SAD) Therapeutics market in future.
 
- Formulate effective sales and marketing strategies by understanding the competitive landscape and byanalyzing the performance of various competitors.
 
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies togain a competitive advantage.
 
- Organize your sales and marketing efforts by identifying the market categories and segments that present
 
maximum opportunities for consolidations, investments and strategic partnerships.- What the next big thing in the global Social Anxiety Disorders (SAD) Therapeutics market landscape?
 
 
Identify, understand and capitalize.1.1 List of Tables 51.2 List of Figures 62 Social Anxiety Disorders (SAD) Therapeutics - Introduction 7
 
2.1 Overview 72.1.1 Types of SAD 7
 
2.2 Etiology and Pathophysiology 72.3 Epidemiology 8
 
2.3.1 The US 82.3.2 Spain 82.3.3 Italy 8
 
2.3.4 Japan 8
 
2.3.5 Germany 82.3.6 France 82.3.7 Pharmaco-economic Burden 82.3.8 Quality of Life (QoL) 8
 
2.3.9 Morbidity 92.4 Symptoms 9
 
2.5 Diagnosis 92.5.1 Diagnostic Criteria for SAD Defined by DSM-IV 9
 
2.5.2 Measurement Scales 102.6 Treatment and Management Pattern 102.6.1 Psychological Treatment 10
 
2.6.2 Pharmacologic Treatment 112.7 Referral Pathway 12
 
2.8 GlobalData Pipeline Report Guidance 133 SAD Therapeutics - Market Characterization 14
 
3.1 Overview 143.2 SAD Therapeutics Market Size (2006-2011) - Global 143.3 SAD Therapeutics Market Forecast (2011-2019) - Global 16
 
3.4 SAD Therapeutics Market Size (2006-2011) - The US 173.5 SAD Therapeutics Market Forecast (2011-2019) - The US 18
 
3.6 SAD Therapeutics Market Size (2006-2011) - France 193.7 SAD Therapeutics Market Forecast (2011-2019) - France 20
 
3.8 SAD Therapeutics Market Size (2006-2011) - Germany 21
 
3.9 SAD Therapeutics Market Forecast (2011-2019) - Germany 223.10 SAD Therapeutics Market Size (2006-2011) - Italy 23
 
3.11 SAD Therapeutics Market Forecast (2011-2019) - Italy 243.12 SAD Therapeutics Market Size (2006-2011) - Spain 25
 
3.13 SAD Therapeutics Market Forecast (2011-2019) - Spain 263.14 SAD Therapeutics Market Size (2006-2011) - The UK 27
 
3.15 SAD Therapeutics Market Forecast (2011-2019) - The UK 283.16 SAD Therapeutics Market Size (2006-2011) - Japan 29
 
3.17 SAD Therapeutics Market Forecast (2011-2019) - Japan 30
 
3.18 Drivers and Barriers 313.18.1 Drivers for the SAD Therapeutics Market 31
 
3.18.2 Barriers for the SAD Therapeutics Market 313.19 Opportunity and Unmet Needs 31
 
3.20 Key Takeaway 324 SAD Therapeutics Market - Competitive Assessment 33
 
4.1 Overview 334.2 Strategic Competitor Assessment 33
 
4.3 Product Profile for the Major Marketed Products in the SAD Therapeutics Market 344.3.1 SSRIs 344.3.2 SNRIs 344.3.3 Benzodiazepines 364.3.4 Monoamine Oxidase Inhibitors 374.4 Key Takeaway 375 SAD Therapeutics - Pipeline Assessment 38
 
5.1 Overview 385.2 Strategic Pipeline Assessment 38
 
5.3 Pipeline by Phases of Development 385.3.1 SAD Therapeutics-Phase II Pipeline 38
 
5.3.2 SAD Therapeutics- Phase I Pipeline 39
 
5.4 SAD Therapeutics Market - Clinical Pipeline by Mechanism of Action. 395.5 Technology Trends Analytic Framework 40
 
5.6 Promising Drugs under Clinical Development 415.7 Profiles of Promising Drugs 42
 
5.7.1 CXB722 425.7.2 PH94B 425.7.3 TGW00AA 435.8 Key Takeaway 44
 
6 SAD Therapeutics - Clinical Trials Mapping 45
 
6.1 Clinical Trials by Region/Country (US, EU5 and Japan) 456.2 Clinical Trials by Phase 46
 
6.3 Clinical Trials by Trial Status 47
 
6.4 Prominent Sponsors 486.5 Top Companies Participating in Therapeutics Clinical Trials 50
 
7 SAD Therapeutics - Strategic Assessment 517.1 Key Events Impacting the Future Market 51
 
7.2 Future Market Competition Scenario 518 SAD Therapeutics - Future Players 53
 
8.1 Introduction 538.2 Company Profiles 54
 
8.2.1 CeNeRx BioPharma 548.2.2 Fabre-Kramer Pharmaceuticals, Inc 548.2.3 Pherin Pharmaceuticals 558.3 Other Companies in the SAD Therapeutics Market 569 SAD Therapeutics - Licensing and Partnership Deals 57
 
10 Appendix 5810.1 Market Definitions 5810.2 Abbreviations 5810.3 Methodology 5910.3.1 Coverage 59
 
10.3.2 Secondary Research 5910.3.3 Forecasting 60
 
10.3.4 Primary Research 6210.3.5 Expert Panel Validation 63
 
10.4 Contact Us 6310.5 Disclaimer 6310.6 Bibliography 63
 
1.1 List of TablesTable 1: FDA and EMEA Approved Medications for the Treatment of SAD 12Table 2: SAD Therapeutics Market, Global, Revenue ($m), 2006-2011 15
 
Table 3: SAD Therapeutics Market, Global, Forecast ($m), 2011-2019 16Table 4: SAD Therapeutics Market, The US, Revenue ($m), 2006-2011 17
 
Table 5: SAD Therapeutics Market, The US, Forecast ($m), 2011-2019 18Table 6: SAD Therapeutics Market, France, Revenue ($m), 2006-2011 19
 
Table 7: SAD Therapeutics Market, France, Forecast ($m), 2011-2019 20
 
Table 8: SAD Therapeutics Market, Germany, Revenue ($m), 2006-2011 21Table 9: SAD Therapeutics Market, Germany, Forecast ($m), 2011-2019 22
 
Table 10: SAD Therapeutics Market, Italy, Revenue ($m), 2006-2011 23Table 11: SAD Therapeutics Market, Italy, Forecast ($m), 2011-2019 24
 
Table 12: SAD Therapeutics Market, Spain, Revenue ($m), 2006-2011 25Table 13: SAD Therapeutics Market, Spain, Forecast ($m), 2011-2019 26
 
Table 14: SAD Therapeutics Market, The UK, Revenue ($m), 2006-2011 27Table 15: SAD Therapeutics Market, The UK, Forecast ($m), 2011-2019 28
 
Table 16: SAD Therapeutics Market, Japan, Revenue ($m), 2006-2011 29
 
Table 17: SAD Therapeutics Market, Japan, Forecast ($m), 2011-2019 30Table 18: Treatment-Emergent Adverse Event Incidence in Short-Term Placebo-Controlled Effexor XR Clinical
 
Trials in SAD Patients 35Table 19: SAD Therapeutics-Phase II Pipeline 38
 
Table 20: SAD Therapeutics-Phase I Pipeline 39Table 21: SAD Therapeutics - Most Promising Drugs Under Clinical Development, 2011 41
 
Table 22: SAD Therapeutics Market, Number of Clinical Trials by Region, 2011 45Table 23: SAD Therapeutics Market, Global, Clinical Trials by Phase of Development (%), 2011 46
 
Table 24: SAD Therapeutics Market, Global, Clinical Trials by Trial Status (%), 2011 47
 
Table 25: SAD Therapeutics Market, Global, Clinical Trials by Prominent Sponsors (%), 2011 49Table 26: SAD Therapeutics Market, Global, Number of Clinical Trials by Top Companies, 2011 50
 
Table 27: CeNeRx BioPharma - CNS Pipeline Products, 2011 54Table 28: CeNeRx BioPharma - SAD Pipeline Products, 2011 54
 
Table 29: Fabre-Kramer Pharmaceuticals - CNS Pipeline Products, 2011 55Table 30: Fabre-Kramer Pharmaceuticals - SAD Pipeline Products, 2011 55

You're Reading a Free Preview

Download
scribd
/*********** DO NOT ALTER ANYTHING BELOW THIS LINE ! ************/ var s_code=s.t();if(s_code)document.write(s_code)//-->